Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.

Fortress Biotech, Inc. (NASDAQ: FBIO) announced through its majority-controlled subsidiary, Journey Medical Corporation, that the U.S. Food and Drug Administration (FDA) has approved Emrosi™ ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care ...

The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release capsules) for the ...

Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi ...

Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over ...

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved minocycline hydrochloride ...

Journey Medical (DERM) received FDA approval for its drug Emrosi for the treatment of rosacea and released its preliminary Q3 ...

The U.S. Food and Drug Administration has approved Journey Medical's drug for the treatment of a long-term skin condition ...

Journey Medical (DERM) announced that the FDA has approved Emrosi, formerly referred to as DFD-29, for the treatment of inflammatory lesions of ...